Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, June Kyu | - |
dc.contributor.author | Hong, JinWoo | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2021-07-30T04:52:16Z | - |
dc.date.available | 2021-07-30T04:52:16Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/1722 | - |
dc.description.abstract | Immuno-oncology (IO) has been an active area of oncology research. Following US FDA approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA-4 monoclonal antibody), in 2011, and of the first oncolytic virus, Imlygic (talimogene laherparepvec), in 2015, there has been renewed interest in IO. In the past decade, ICIs have changed the treatment paradigm for many cancers by enabling better therapeutic control, resuming immune surveillance, suppressing tumor immunosuppression, and restoring antitumor immune function. However, ICI therapies are effective only in a small subset of patients and show limited therapeutic potential due to their inability to demonstrate efficacy in 'cold' or unresponsive tumor microenvironments (TMEs). Relatedly, oncolytic viruses (OVs) have been shown to induce antitumor immune responses, augment the efficacy of existing cancer treatments, and reform unresponsive TME to turn 'cold' tumors 'hot,' increasing their susceptibility to checkpoint blockade immunotherapies. For this reason, OVs serve as ideal complements to ICIs, and multiple preclinical studies and clinical trials are demonstrating their combined therapeutic efficacy. This review will discuss the merits and limitations of OVs and ICIs as monotherapy then progress onto the preclinical rationale and the results of clinical trials of key combination therapies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.3390/ijms21228627 | - |
dc.identifier.scopusid | 2-s2.0-85096094530 | - |
dc.identifier.wosid | 000594230700001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.21, no.22 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 21 | - |
dc.citation.number | 22 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | VESICULAR STOMATITIS-VIRUS | - |
dc.subject.keywordPlus | NEWCASTLE-DISEASE VIRUS | - |
dc.subject.keywordPlus | HERPES-SIMPLEX-VIRUS | - |
dc.subject.keywordPlus | HUMAN-MELANOMA TUMORS | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | TALIMOGENE LAHERPAREPVEC | - |
dc.subject.keywordPlus | VACCINIA VIRUS | - |
dc.subject.keywordPlus | REOVIRUS ONCOLYSIS | - |
dc.subject.keywordPlus | ADENOVIRUS VECTORS | - |
dc.subject.keywordPlus | COXSACKIEVIRUS A21 | - |
dc.subject.keywordAuthor | oncolytic virus 1 | - |
dc.subject.keywordAuthor | immune checkpoint inhibitor 2 | - |
dc.subject.keywordAuthor | immuno-oncology 3 | - |
dc.subject.keywordAuthor | combination therapy 4 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.